Home > Healthcare > Biotechnology > Biopharma > Gene Therapy Market

Gene Therapy Market Trends

Report ID: GMI5883
Published Date: May 2023
Report Format: PDF

Download Free Sample

Gene Therapy Market Trends

Some key trends in the market includes advancements in gene editing technologies, increasing number of clinical trials, and expansion of gene therapies into rare diseases. The development and refinement of gene editing technologies, such as CRISPR-Cas9, zinc finger nucleases (ZFNs), and TALENs, have revolutionized the field of gene therapy. These technologies enable precise and targeted modifications to the genetic material, opening up new possibilities for treating genetic disorders and other diseases.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for gene therapy was worth USD 9 billion in 2023 and is projected to record growth at 19.4% CAGR from 2024 to 2032 owing to the expansion and development of advanced medicines and gene delivery technologies.

The non-viral vector segment accounted for a sizable revenue share in 2022 and is estimated to grow significantly through 2032 as non-viral vectors are less likely to trigger immune responses and are associated with lower toxicity, which makes them suitable for clinical use.

The North America market is set to grow at a rate of 19.2% over 2023-2032 attributed to the strong financial and government support, availability of advanced healthcare infrastructure, and robust R&D ecosystem.

The top players engaged in the global market are Merck KGaA, REGENXBIO, Inc., Oxford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd, bluebird bio, Inc., Novartis AG, Orchard Therapeutics, Gilead Lifesciences, Inc., BENITEC BIOPHARMA, Sibiono GeneTech Co., Ltd, and Shanghai Sunway Biotech Co., Ltd.